David Hoang
Stock Analyst at Deutsche Bank
(1.86)
# 3,256
Out of 5,005 analysts
45
Total ratings
40%
Success rate
-8.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $15.89 | +170.61% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $27.28 | +31.96% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $22.64 | -47.00% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $21.80 | +60.55% | 5 | May 21, 2025 | |
| ALKS Alkermes | Maintains: Buy | $40 → $52 | $31.06 | +67.42% | 2 | Mar 27, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $39.61 | +69.15% | 3 | Feb 11, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $111 | $54.38 | +104.12% | 1 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $15.42 | +101.04% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $15.81 | +311.13% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $120.30 | +46.30% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $15.01 | -20.05% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $137.03 | +15.30% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.73 | +304.62% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.90 | +171.19% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.86 | +229.22% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $456.35 | -51.79% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $36.12 | +121.48% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $2.57 | +16.73% | 1 | Dec 7, 2022 |
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $15.89
Upside: +170.61%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $27.28
Upside: +31.96%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $22.64
Upside: -47.00%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $21.80
Upside: +60.55%
Alkermes
Mar 27, 2025
Maintains: Buy
Price Target: $40 → $52
Current: $31.06
Upside: +67.42%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $39.61
Upside: +69.15%
Praxis Precision Medicines
Feb 11, 2025
Initiates: Buy
Price Target: $111
Current: $54.38
Upside: +104.12%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $15.42
Upside: +101.04%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $15.81
Upside: +311.13%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $120.30
Upside: +46.30%
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $15.01
Upside: -20.05%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $137.03
Upside: +15.30%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.73
Upside: +304.62%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $5.90
Upside: +171.19%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.86
Upside: +229.22%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $456.35
Upside: -51.79%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $36.12
Upside: +121.48%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $2.57
Upside: +16.73%